en · de · es · fr · pt
sr9009-notes.peptides5388.com › Guide › Handling, Analysis, And Regulation — Reference Sheet

Handling, Analysis, And Regulation — Reference Sheet

By Editorial Desk · published 2026-04-20 · last reviewed 2026-05-28 · Guide

LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-05-28. Where a claim depends on a specific study, the study is described rather than over-claimed.

Handling, Analysis, and Regulation

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Sr9009 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderCommon supplier description
SolubilitySoluble in DMSO and ethanolLow solubility in water
Typical storage−20 °C, desiccated, darkFor research samples
Analytical methodLC-MS/MSUsed for detection and quantification
Regulatory statusProhibited in sportWADA metabolic modulator class

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Related pages on this site

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Background from the literature

==== Effect on bacteria ==== Silver nanoparticles are experimentally shown to inhibit autotrophic nitrifying bacterial growth (86±3%) more than Ag+ ions (42±7%) or AgCl colloids (46±4%). Silver nanoparticle-inhibited heterotrophic growth (55±8%) in Escherichia coli is best observed at lower concentrations, between 1.0 uM and 4.2 uM. This is less than Ag+ ions (~100%), but greater than AgCl colloids (66±6%). The actual cause of these results is undetermined as growth conditions and cell properties differ between nitrifying bacteria and heterotrophic E. coli. Studies conducted in natural lake environments show less response from bacterioplankton than in laboratory environments when exposed to similar concentrations of silver nanoparticles. This may be due to the binding of free Ag+ ions to dissolved organic matter in lake environments, rendering the Ag+ unavailable. Within toothpaste, Ag+ ions have been shown to have a stronger effect on gram-negative bacteria than on gram-positive bacteria. In comparison to other nanoparticles, such as gold, silver tends to have a broader antimicrobial effect, which is another reason why it is incorporated into so many products. Ag+ is less effective on gram-positive bacteria due to the thick layer of peptidoglycan around them that gram-negative species lack. Approximately half of the peptidoglycan wall is composed of teichoic acids linked by phosphodiester bonds, which results in an overall negative charge in the peptidoglycan layer.

The presence of autoantibodies against citrullinated proteins in rheumatoid arthritis patients was first described in the mid-1970s when the biochemical basis of antibody reactivity against keratin and filaggrin was investigated. Subsequent studies demonstrated that autoantibodies from RA patients react with a series of different citrullinated antigens, including fibrinogen, deiminated Epstein–Barr virus nuclear antigen 1 and vimentin, which is a member of the intermediate filament family of proteins. Several assays for detecting ACPAs were developed in the following years, employing mutated citrullinated Vimentin (MCV-assay), filaggrin-derived peptides (CCP-assay) and viral citrullinated peptides (VCP-assay). A 2006 clinical study showed that anti viral citrullinated peptide (VCP) antibodies of the IgG and IgA isotypes represent a discriminating specific marker of rheumatoid arthritis from other chronic arthritides and disease controls, suggesting an independent production of each isotype. In 2010, ACPA testing has become substantial part of The 2010 ACR-EULAR classification criteria for rheumatoid arthritis.

KIAA0232 is predicted to have nuclear localization. KIAA0232 is predicted by the tools at ExPASy to be highly phosphorylated, with 15 tyrosine specific sites, 25 threonine specific sites, and 103 serine specific sites. KIAA0232 is experimentally known to interact with YWHAZ, DYRK1A, and DYRK1B. via two hybrid interaction experiments. YWHAZ is an apoptotic path regulator known to bind to phosphoserine proteins. DYRK1A/B are dual-specificity tyrosine kinases. This corroborates the post-translational modification predictions.

Sources: en.wikipedia.org

Reference notes

Phospholipase D2 (PLD2) binds PIP2 and localizes with lipid rafts. Increases in cholesterol overcome PIP2 binding and sequester PLD2 into GM1 lipid rafts away from its substrate phosphatidylcholine. Efflux of cholesterol causes PLD2 to translocate to PIP2 domains where it is activated by substrate presentation. Both PIP2 signaling and cholesterol signaling regulate the enzyme. Angiotensin converting enzyme (ACE2) is regulated by PIP2 localization. The ACE2 enzyme is palmitoylated which drives the protein into GM1 lipids. The enzyme also bind to PIP2 which moves it out of the endocytic pathway. The drug hydroxychloroquine blocks ACE2 interaction with PIP2 in multiple cell types shifting its localization. PIP2 binding proteins PH domain PIP2/palmitate proteins GABAA receptor

=== End-of-life care === In the final stages of end-of-life care, midazolam is routinely used at low doses via subcutaneous injection to help with agitation, restlessness, or anxiety in the last hours or days of life. Midazolam is considered a first-line agent in palliative continuous deep sedation therapy—when it is necessary to alleviate intolerable suffering not responsive to other treatments, but the need for higher doses is rare.

Half & Half is an American television sitcom created by Jeffrey Klarik and executive-produced by Yvette Lee Bowser through her Sister Lee Productions banner that aired on UPN from September 23, 2002, to May 15, 2006 (related to the Fox comedy show, Living Single that aired out in 1993 until 1998). It was co-produced by CBS Studios under one of its former aliases, Eye Productions, Inc. Set in San Francisco, California, the show centers on the lives of two paternal half-sisters in their early adulthood who were estranged throughout their childhood, and are finally developing a close relationship. The show was the second-most-watched on UPN's Monday night line-up (next to Girlfriends) and fourth overall on the network. The series was almost renewed for a fifth season by UPN's successor network, The CW, but due to several circumstances — including the network's contractual obligation to pick up Reba, the last-minute renewal of All of Us, and the pick-up of the Girlfriends spin-off The Game — the series was left off the network's Autumn 2006 schedule and canceled. Outside of the United States, the series has aired in reruns on Global TV in Canada, Trouble in the United Kingdom and in local syndication channels in the United States, including Bounce TV, TV One, Cleo TV, BET Her and Dabl. The series is available to stream on Paramount+ and Amazon Prime Video.

Sources: en.wikipedia.org

Notes from published material

The tournament's official instrumental theme music was composed by Zachary Aaron Golden. Throughout March 2025, FIFA released remixes of the theme for each host city by local producers. The first single from the official soundtrack album, "Lighter" by American country rap performer Jelly Roll and Mexican singer Carín León, was released on March 20, 2026; the song garnered a mixed reception from listeners and critics, with some having falsely assumed that it was meant to be the tournament's official song. The official song "Dai Dai" by Colombian singer Shakira and Nigerian singer Burna Boy was released on May 15, 2026, followed by the official album on June 5, 2026. The official anthem "DNA (More Than a Game)" by French producer David Guetta, featuring Italian tenor Andrea Bocelli, South Korean-American singer Ejae, and American rapper Megan Thee Stallion was released on June 10, 2026. Instrumental song "Sirius" by British rock band the Alan Parsons Project, known for having been played at Chicago Bulls home games since 1984, was used as the theme song for the entrances of the national teams before each match during the first matchday of the group stage. For all subsequent matches, a special walkout remix of "Dai Dai" was used. "DNA (More Than a Game)" and "Titanium (David Guetta and Morten Remix)" were played after the national anthems and before the kickoff.

Fourier-transform ion cyclotron resonance mass spectrometry (also known as Fourier-transform mass spectrometry) is a type of mass spectrometry used for determining the mass-to-charge ratio (m/z) of ions based on the cyclotron frequency of the ions in a fixed magnetic field. The ions are trapped in a Penning trap where they are excited to a larger cyclotron radius by an oscillating electric field perpendicular to the magnetic field. The excitation also results in the ions moving in phase (in a packet). The signal is detected as an image current on a pair of plates which the packet of ions passes close to as they cyclotron. The resulting signal is called a free induction decay (fid), transient or interferogram that consists of a superposition of sine waves. The useful signal is extracted from this data by performing a Fourier transform to give a mass spectrum. Single ions can be investigated in a Penning trap held at a temperature of 4 K. For this the ring electrode is segmented and opposite electrodes are connected to a superconducting coil and the source and the gate of a field-effect transistor. The coil and the parasitic capacitances of the circuit form a LC circuit with a Q of about 50 000. The LC circuit is excited by an external electric pulse. The segmented electrodes couple the motion of the single electron to the LC circuit. Thus the energy in the LC circuit in resonance with the ion slowly oscillates between the many electrons (10000) in the gate of the field effect transistor and the single electron.

In food packaging, sealing plays an important role in ensuring food safety, product preservation, and package integrity. Sealing is used to hermetically close bags made of plastic or multilayer materials, such as pouches, trays, or flexible films. More employed techniques in food industry include heat sealing, which requires the use of hot air, ultrasound, or induction to generate heat, laser sealing, and cold sealing. These processes guarantee a barrier against external agents, such as oxygen, moisture, light, and microorganisms, preventing contamination and extending the product's shelf life. The quality of the seal is a critical parameter: a defective seal can lead to the degradation of organoleptic properties and also compromise food safety. For this reason, the food industry adopts international quality control standards to assess the integrity of the sealing.

On behalf of the Mexican nation I send my message of protest to all the countries of the world for the new outrages committed by the militarist imperialism that has attacked Belgium and Holland, without encountering any other obstacle than the heroic defense of the invaded peoples, while other countries, forgetting their responsibility, have assumed an expectant and indolent attitude. When General Avila Camacho took office as President of Mexico in December 1940, neutrality was less firm. After the invasions of Greece and Yugoslavia in April 1941, the new president declared:

Sources: en.wikipedia.org

Frequently asked questions

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.

How is SR9009 detected?

Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.

How should SR9009 be stored?

Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Network